Lixte Biotechnology Holdings, Inc. (LIXT) Stock Score, Valuation & Financial Research

Lixte Biotechnology Holdings, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for LIXT

Lixte Biotechnology Holdings, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 7.21. These figures are a research snapshot, not a buy or sell recommendation.

What Lixte Biotechnology Holdings, Inc. does

Lixte Biotechnology Holdings, Inc. is a drug discovery company focused on developing new treatments. It employs biomarker technology to identify crucial enzyme targets associated with serious, widespread diseases, then designs innovative compounds to act upon these targets. The company's primary focus lies in protein phosphatase inhibitors, which are being investigated for use both independently and in combination with cytotoxic agents, radiation therapy, and immune checkpoint blockers. Its pipeline includes two main categories of compounds, currently in various stages of pre-clinical and clinical development. The LB-100 series consists of novel chemical entities aimed at treating various cancers, vascular diseases, and metabolic disorders. Meanwhile, the LB-200 series is being developed to address chronic hereditary conditions, such as Gaucher's disease, as well as specific cancers and neurodegenerative ailments. Lixte Biotechnology Holdings, Inc. has forged significant alliances, including a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc. Additionally, it has collaboration agreements for investigator-initiated clinical trials with the Spanish Sarcoma Group, the Netherlands Cancer Institute, and the Oncode Institute. Founded in 2005, the company is headquartered in Pasadena, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings to fund the research, development, and clinical testing of its proprietary cancer drug candidates and medical technology, with the goal of eventually commercializing these therapies or licensing them to larger pharmaceutical partners.

Products and services

  • The company's primary product candidate is LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A) currently in clinical trials for various cancers. It also holds the LiGHT System, a proprietary med-tech platform for tumor treatment.

Brands and product families

  • LB-100 — Lead clinical PP2A inhibitor compound. Source
  • LiGHT System — Proprietary med-tech platform for tumor treatment. Source

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes third-party contract research organizations to conduct clinical trials and preclinical studies; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • The Netherlands Cancer Institute (NKI) — A research collaboration to test whether cells carrying mutations found in cancer can be eliminated by treatment with LIXTE’s proprietary compound LB-100. Source

Business strengths to evaluate

  • Proprietary patent portfolio covering LB-100 and the LiGHT System Source

Business risks and research considerations

  • History of operating losses and dependence on external financing Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

LIXT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 7.21
Market capitalization:
89.11M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -8.69M
Free cash flow:
USD -3.07M
Cash:
USD 12.67M
Total debt:
USD 1.1M
EPS:
USD -1.00

What stands out

  • Free cash flow is USD -3.07M, negative for the stored period.
  • The balance sheet shows USD 12.67M of cash versus USD 1.1M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 11.57M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for LIXT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can LIXT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is LIXT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for LIXT to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of LIXT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research LIXT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.